Evidence map›Paper›PMID 40511196›Full record

ArticleJournal of pharmacy & bioallied sciences2025

Exploring Lymphocyte Immunotherapy as a Treatment for Recurrent Miscarriage: A Case Study of Immune System Modulation and Positive Clinical Pregnancy Rate.

Achal D Warhade, Akash More, Namrata Anjankar, Puja Dhamija, Prajwal Warhade

Abstract readCase Reports
In one paragraph

Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Achal D WarhadeDepartment of Clinical Embryology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
Akash MoreSenior Embryologist, Wardha Test Tube Baby Centre (WTTBC), Acharya Vinoba Bhave Rural (AVBR) Hospitals, Sawangi (Meghe), Wardha, Maharashtra, India.
Namrata AnjankarAssociate Professor and Co-Convener, School of Allied Health Science, Datta Meghe Institute of Higher Education and Research (DU), Sawangi (Meghe), Wardha, Maharashtra, India.
Puja DhamijaDepartment of Clinical Embryology, School of Allied Health Sciences, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
Prajwal WarhadeAdministrative Officer, Acharya Vinoba Bhave Rural Hospital, Sawangi (Meghe), Wardha, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case study reviews the use of Lymphocyte Immunotherapy (LIT) in a 28-year-old female patient who had a history of recurrent first-trimester miscarriages and failed intracytoplasmic sperm injection (ICSI) cycles. She had good ovarian reserve, normal semen analysis, and negative autoimmune tests but experienced four early miscarriages, which suggested an immune-mediated issue. LIT was chosen as a treatment option to address the possibility of immune system dysregulation contributing to pregnancy loss. LIT is the process of infusing the husband's lymphocytes to promote maternal tolerance of paternal antigens, reducing the possibility of immune foetal rejection. A received LIT was performed six weeks prior to a fresh ICSI cycle, with successful fertilization and transfer of embryos. There is evidence that positive outcomes occurred in serial ultrasounds and hormone levels at 6, 8, and 12 weeks with subsequent birth at term of a healthy baby. This case points to the possibility of using LIT as a therapeutic intervention in the treatment of unexplained recurrent miscarriage in patients who had previously failed previous assisted reproductive treatments. While the mechanism of action for LIT remains unknown, it would seem to somehow modulate the immune responses so that pregnancy results in better outcomes. This case may thus provide new evidence for LIT as a possible management strategy for those with immune causes of recurrent pregnancy loss (RPL) but warrants additional studies to optimize its use and effectivity.

Indexed as

Fertility treatmentimmune systemLymphocyte Immunotherapypregnancy outcomesrecurrent miscarriageunexplained infertility

Identifiers

PMID40511196
PMCPMC12156657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.